Polycystic Ovary Syndrome Treatment Market Report 2023: Sector is Expected to Reach $1.5 Billion by 2030 at a CAGR of 4.9%
As per Zion Market Research, Global Polycystic Ovary Syndrome Treatment Market Report 2023: Sector is Expected to Reach $1.5 Billion by 2030 at a CAGR of 4.9%. Polycystic ovary syndrome (PCOS) is a hormonal endocrine disorder and affects females of 15–49 years. This disorder is characterized by the development of cysts on the ovaries resulting in an insufficiency of the ovulation embarking hormone in the female body. As per the CDC (Centers for Disease Control & Prevention), PCOS is the most normal cause of female infertility. Furthermore, the advancement of this condition can induce metabolic abnormalities, which can result in the development of type II diabetes, if the syndrome is not cured on time. The acuteness of the disorder surges the peril of advancing endometrial and uterine cancers in patients. Therefore, timely diagnosis and effective treatment are important for a successful recovery.
Some of the leading players in the global market are Bayer AG; AstraZeneca; Abbott; Merck KGaA; Pfizer, Inc.; Sanofi; Novartis AG; and Bristol-Myer Squibb Company.
Rising Awareness Amongst The Patients On Disorder Will Boost The Global Polycystic Ovary Syndrome (PCOS) Treatment Market
The incidence of the PCOS disorder is growing, which is stimulating the global polycystic ovary syndrome (PCOS) treatment market. In addition, the rising awareness amongst the patient population concerning the accessibility of the treatment is spurring the growth of the market. The PCOS can lead to obesity, infertility, and hirsutism, hence, the consciousness level in the people is augmenting. This aspect is increasing the adoption of the PCOS treatments and expected to propel the market. In addition, the growing implementation of combination drugs along with growing adoption amongst the patients is projected to boost the revenue of the market. Nevertheless, the lack of drug authorization from the FDA (Food and Drug Administration) and possible side effects linked with generics can impact market growth during the forecasted period.
The global polycystic ovary syndrome (PCOS) treatment market is bifurcated on the basis of drug class, surgery, and regional analysis. Based on the drug class, the market is divided into oral contraceptives, insulin-sensitizing agents, antiandrogens, anti-obesity, and antidepressants. Based on the surgery, the market is divided into laparoscopic ovarian drilling and ovarian wedge resection.
Asia Pacific Region To Dominate The Global Polycystic Ovary Syndrome (PCOS) Treatment Market
Based on geographical analysis, the global polycystic ovary syndrome (PCOS) treatment market is divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The North America region is the most emerged market accompanied by Europe. The surging incidence of overweight and obesity is inducing a surge in the number of women suffering from PCOS, which is one of the major aspects contributing to market development in North America. Furthermore, the augmenting awareness concerning the benefits of regular checkups is resulting in a rise in the number of new cases being identified each year in this region. The Asia Pacific region — including China and India — accounted for the major population base. The administrations in these countries are aiming at controlling the increasing prevalence of PCOS by accomplishing programs that support the analysis & therapeutics of this disorder and the required modification in lifestyle. These aspects are likely to spur the Asia Pacific market in the future.
Company Profiles
- Sanofi S.A.
- Amneal Pharmaceuticals, Inc.
- Laurus Labs Limited
- Zydus Pharmaceuticals, Inc.
- Prasco Laboratories
- Reddy’s Laboratories
- Cadila Pharmaceuticals
- Novartis International AG
- Concordia Pharmaceuticals Inc.
- Covis Pharmaceuticals, Inc.
- Cardinal Health
- Aphena Pharma Solutions — Tennessee, LLC
- MYLAN N.V.
- McKesson
- TEVA PHARMACEUTICAL AND CHEMICAL INDUSTRIES INDIA PRIVATE LIMITED
- Lupin Pharmaceutical Limited
- GUJARAT SUN PHARMACEUTICAL INDUSTRIES PRIVATE LIMITED
The global polycystic ovary syndrome (PCOS) treatment market is segmented as follows:
By drug class:
- Insulin-sensitizing Agents
- Antidepressants
- Oral Contraceptives
- Antiandrogens
- Anti-obesity
By surgery:
- Ovarian Wedge Resection
- Laparoscopic Ovarian Drilling
By region:
- North AmericaThe U.S.Canada
- EuropeFranceThe UKSpainGermanyItalyRest of Europe
- Asia PacificChinaJapanIndiaSouth KoreaSoutheast AsiaRest of Asia Pacific
- Latin AmericaBrazilMexicoRest of Latin America
- Middle East & AfricaGCCSouth AfricaRest of Middle East & Africa
About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us — after all — if you do well, a little of the light shines on us.
Contact Us:
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +49–322 210 92714 USA/Canada Toll-Free №1–855–465–4651 Email: sales@zionmarketresearch.com Website: https://www.zionmarketresearch.com